Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons.
Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons.
复制标题
DOI：
10.11005/jbm.2015.22.4.151
复制
发表时间：
2015-11
影响因子：
--
通讯作者：
Kim DY
中科院分区：
文献类型：
--
作者：
Kim KM;Rhee Y;Kwon YD;Kwon TG;Lee JK;Kim DY
双膦酸盐是治疗骨质疏松症的最广泛的处方药物，也用于恶性骨转移、多发性骨髓瘤和佩吉特病，并对这些疾病提供治疗效果。然而，据报告，颌骨骨坏死（ONJ）的发生可能与双膦酸盐暴露有关，并且有许多病例涉及该问题。因此，需要对这种疾病有更明确的定义和治疗指南。美国骨与矿物质研究学会（ASBMR）和美国口腔颌面外科医生协会（AAOMS）报告了关于双膦酸盐相关ONJ（BRONJ）的声明，最近提交了修订版。在修订版中，诊断BRONJ变更为药物相关ONJ（MRONJ），这反映了考虑到ONJ也发生于地舒单抗（一种核因子-κ B配体受体激活剂（RANKL）抗体家族的骨吸收抑制剂）和贝伐珠单抗（一种抗血管生成抑制剂）。2009年，当地相关组织也报告了有关ONJ的声明，该声明已成为韩国临床治疗的依据。除了AAOMS和ASBMR的新官方立场外，随着ONJ临床经验的增加，还需要对2009年当地声明进行修订。因此，韩国骨与矿物质研究学会（KSBMR）和韩国口腔颌面外科医生协会（KAOMS）共同成立了一个委员会，负责编写关于MRONJ的官方声明，并审查了最近的本地和国际数据，以提出针对韩国本地情况定制的指南。
Bisphosphonates are the most widely prescribed drugs for the treatment of osteoporosis, and are also used in malignant bone metastases, multiple myeloma, and Paget's disease, and provide therapeutic efficacy on those diseases. However, it was reported that occurrence of osteonecrosis of the jaw (ONJ) could be related with bisphosphonate exposures, and there have been many cases regarding this issue. Therefore, a clearer definition and treatment guidelines were needed for this disease. The American Society for Bone and Mineral Research (ASBMR) and American Association of Oral and Maxillofacial Surgeons (AAOMS) reported statements on bisphosphonate-related ONJ (BRONJ), and a revised version was recently presented. In the revised edition, the diagnosis BRONJ was changed to medication-related ONJ (MRONJ), which reflects a consideration of the fact that ONJ also occurs for denosumab, a bone resorption inhibitor of the receptor activator of nuclear factor-kappa B ligand (RANKL) antibody family, and bevacizumab, an anti-angiogenesis inhibitor. In 2009, a statement on ONJ was also reported locally by a relevant organization, which has served as basis for clinical treatment in Korea. In addition to the new official stance of the AAOMS and ASBMR, with an increasing pool of ONJ clinical experience, a revised version of the 2009 local statement is needed. As such, the Korean Society for Bone and Mineral Research (KSBMR) and the Korean Association of Oral and Maxillofacial Surgeons (KAOMS) have collectively formed a committee for the preparation of an official statement on MRONJ, and have reviewed recent local and international data to propose guidelines customized for the local Korean situation.